Evidence map›Paper›PMID 42681444›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Acute Incompatible Red Blood Cell Transfusion in Mice.

Ryan P Jajosky, Brock D Hughes, Caitlin L Cepeda, Sasikala Muthusamy, Andre J H Wittig, Wenhui Li, Samata P Varadkar, Shang-Chuen Wu, William O Scott, Carter J Stowell and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ryan P JajoskyDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Brock D HughesDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Caitlin L CepedaDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Sasikala MuthusamyDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Andre J H WittigDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Wenhui LiDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Samata P VaradkarDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Shang-Chuen WuDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
William O ScottDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Carter J StowellDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Sadie LarsonDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Katelyn SturgisDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Connie M ArthurDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Sean R StowellDivision of Transfusion Medicine, Mass General Brigham, Harvard Medical School, Boston, MA, USA. srstowell@bwh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alloantibodies, which can arise naturally in early life or after exposure to allogeneic red blood cells (RBCs), can pose a significant risk to blood transfusion. When patients with alloantibodies receive incompatible RBCs, they may experience potentially fatal hemolytic transfusion reactions (HTRs). Transfusion services work to prevent such reactions by identifying compatible blood; however, complications can still occur, especially in patients with complex alloantibody profiles. Given the consequences of these reactions clinically, various preclinical models have been developed to study incompatible RBC transfusions and their consequences. These models provide valuable insights into the mechanisms of HTRs and suggest potential preventive strategies. We will describe key considerations when using preclinical models to study the overall consequences of incompatible RBC transfusions, using the KEL model as an example.

Indexed as

Blood Group IncompatibilityErythrocytesErythrocyte TransfusionAnimalsHumansIsoantibodiesMiceTransfusion ReactionIsoantibodiesAntigen modulationIncompatiblePreclinical modelsRed blood cellsTransfusion

Identifiers

PMID42681444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.